***Background.*** Marijuana (MJ) use is prevalent among HIV-infected persons. Cellular and animal models suggest that cannabinoids may affect immune modulation and HIV disease processes, but evidence on the effects of MJ use in HIV-infected persons is limited.

***Methods.*** We conducted an observational cohort study of HIV-infected adults initiating their first antiretroviral therapy (ART) at the Vanderbilt Comprehensive Care Clinic. Self-reported MJ use in the last 7 days was assessed by a dedicated intake form at each visit. Associations between MJ use and body mass index (BMI), CD4 T cell count, and HIV RNA levels at each visit were determined. Nine random effects models adjusted for age, sex, and race were used to isolate the impact of changing MJ use on outcomes.

###### 

Descriptive statistics for patients reporting MJ use at ≥1 visit vs never reporting MJ use

                                                     No MJ use      MJ use ≥1 visit
  -------------------------------------------------- -------------- -----------------
  **Total**                                          811            199
  **Gender**                                                        
  **Male**                                           584 (72%)      164 (82%)
  **Race**                                                          
  **African American**                               293 (36%)      88 (44%)
  **Caucasian**                                      404 (50%)      104 (52%)
  **Age at ART Initiation**                          36             34
  **Mean (SE) BMI across visits (kg/m^2^)**          27.19 (0.23)   25.76 (0.42)
  **Mean (SE) CD4 count across visits (cells/µl)**   487 (10)       477 (23)

###### 

Estimated coefficients (95% CI) by different specifications of self-reported MJ use

                                                        Ever MJ use (Yes/No)   MJ use in last 7 days (Yes/No)   Times MJ used in last 7 days
  ----------------------------------------------------- ---------------------- -------------------------------- ------------------------------
  **CD4 count**                                         0.13 (-.42--1.88)      -0.005 (-0.28--0.15)             -0.001 (-0.008--0.001)
  **BMI**                                               -0.80 (-1.73--0.13)    -0.11 (-0.35--0.13)              -0.02 (-0.05--0.01)
  **Odds of detectable viral load (\>400 copies/mL)**   2.0\* (1.1--3.5)       1.2 (0.7--2.2)                   0.99 (0.91--1.07)

\*p\<0.05; all others non-significant.

***Results.*** 4290 patient-visits from 2008 to 2011 were available from 1010 patients (Table 1). Overall, there were no statistically significant differences in CD4 count and BMI across multiple models with various measures of MJ use (Table 2). Persons who reported MJ use at any time during follow up were more likely to have at least one HIV-1 RNA \>400 copies/mL.

***Conclusion.*** Self-reported MJ use in the prior 7 days was not associated with changes in BMI, CD4 count, or detectable HIV RNA in HIV-infected persons starting ART. This suggests that active MJ use did not significantly impact these measures. Associations between MJ use and HIV RNA suppression on ART require further study.
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